The Melanoma Immune Oncology Research Group (MIORG) is a cancer research group established to design new tools that optimally detect patients’ eligibility to treatments using the immune system to fight cancer and to develop new combinatory therapies that unleash the full power of these treatments to unresponsive patients.
Immunotherapies that target immune checkpoint regulatory (ICR) molecules have become standard treatments for metastatic melanoma and other cancer types, achieving impressive clinical improvements. Unfortunately, many patients are resistant to these treatments.
Our vision is to conduct world-class research to unleash the benefits of immune checkpoint therapies (ICT) to refractory cancer patients using metastatic melanoma as the main cancer model.
By applying state-of-the-art technologies, including Mass Cytometry and Digital Spatial Profiling (NanoString), we are uncovering novel pathways associated with ICT resistance, mostly involved in the mechanisms of T lymphocyte suppression, which will provide new directions towards combinatory therapies for metastatic cutaneous and uveal melanoma.
Our research is aligned with sustainable development by engaging a participatory society for citizens. We are committed to promoting equal opportunities to enable all people to have access to the most recent updates related to the field of metastatic melanoma prognostication and therapy in Finland and worldwide.